// App-Quantinova.ai

1259 : Comparable 3-Year Disease-Free Survival Regardless of Anti-Thymocyte Globulin Inclusion in Pediatric Myeloablative Cord Blood Transplantation for Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Doris M. Ponce

Principal Investigators

  • Rodney Sparapani

  • Junfang Chen

  • Vanderson Rocha

  • Daniel H. Fowler

  • Mary Eapen

  • Juliet N. Barker

  • Miguel-Angel Perales

Medical Centers

  • Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY

  • Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom

  • Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD

  • Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI

  • Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Major Histocompatibility Complex, Class I, A

  • Major histocompatibility complex, class II, DR beta 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved